▲ bullish
Impact
PhasePhase 2 (pivotal)
Time to marketNDA submission planned for Q1 2027 under accelerated approval pathway. If accepted and approved under standard review timelines, potential FDA decision could come in late 2027 or early 2028.
rezatapopt Updated Nov 11
Q1 2027
Next catalyst
NDA filing · Q1 2027 · platinum-resistant/refractory ovarian cancer with a TP53 Y220C mutation
What to watch
The next catalyst is the late-breaking oral presentation of updated PYNNACLE Phase 2 data at ENA 2026 on November 20, 2026, roughly 9 days away. Positive data could reinforce the NDA submission narrative and support the stock, while disappointing results (weaker efficacy or safety signals) could undermine the accelerated approval path. The NDA submission itself, planned for Q1 2027, is the next major binary event after ENA.
Bull case
- Rezatapopt is a first-in-class oral p53 Y220C reactivator addressing a high-unmet-need population with no approved targeted therapy for this mutation.
- Phase 2 PYNNACLE data showed a 46% overall response rate with a 10-month median duration of response in 76 evaluable platinum-resistant/refractory ovarian cancer patients, a heavily pretreated population.
- FDA granted both Fast Track and Orphan Drug designations in October 2026, signaling regulatory support and potential for expedited review.
Bear case
- Rezatapopt is PMVP's only clinical-stage asset; any clinical setback or regulatory delay would leave the company with no pipeline and limited value.
- The company reported a net loss of $34.37M in Q3 2026 alone, and while it raised $50M in an oversubscribed offering, the cash burn rate is high for a micro-cap stock trading at $1.26.
- Multiple institutional holders (Morgan Stanley, Jane Street, RBC) significantly trimmed or nearly exited their positions in Q2 2026, signaling caution from sophisticated investors.